Levetiracetam Accord (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a central role in neurotransmitter release. This binding modulates vesicle exocytosis, decreasing neuronal hyper‑excitability and stabilising synaptic transmission, thereby lowering the likelihood of seizure initiation without directly affecting ion channels.

The dose of Levetiracetam Accord is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. No fixed regimen is provided here; the prescriber will set the appropriate dosage and titration schedule.

Levetiracetam is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only when the potential benefit justifies any possible risk. Small amounts are excreted in breast milk, so breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Compared with many traditional antiepileptics, levetiracetam has a distinct mechanism (SV2A modulation) and a relatively low potential for drug‑enzyme interactions. It is often favoured for its simple dosing, minimal impact on hepatic metabolism, and a side‑effect profile that lacks significant sedation or cognitive impairment seen with some older agents.

Levetiracetam Accord should be stored at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

Levetiracetam Accord is taken orally, usually as a tablet or oral solution, with or without food. The exact administration schedule—once daily, twice daily, or more—depends on the prescriber’s instructions and the individual patient’s therapeutic needs.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and the emergence of suicidal thoughts or depressive symptoms. Patients should be monitored for any skin rash, mood changes, or signs of hypersensitivity and seek immediate medical attention if these occur.

Levetiracetam Accord is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment who may require dose adjustment, and it should be avoided in patients where the risk of serious skin reactions or psychiatric side effects outweighs potential benefits.